Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 2/20 | 0.33 |
| ▸ | VNN1 | O95497 | 6/20 | 0.32 |
| ▸ | NAA50 | Q9GZZ1 | 2/20 | 0.31 |
| ▸ | CHAT | P28329 | 1/20 | 0.31 |
| ▸ | EP300 | Q09472 | 1/20 | 0.31 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.31 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18823996 | 0.96 | AURKA (0.37) | PTGS1KCNH2AURKAVNN1NAA50 | |
| SCHEMBL21515153 | 0.91 | PTGS1 (0.33) | PTGS1KCNH2AURKAVNN1NAA50 | |
| SCHEMBL18811318 | 0.91 | PTGS1 (0.33) | PTGS1KCNH2AURKAVNN1NAA50 | |
| SCHEMBL23476800 | 0.91 | PTGS1 (0.33) | PTGS1KCNH2AURKAVNN1NAA50 | |
| SCHEMBL18823995 | 0.90 | VNN1 (0.34) | PTGS1KCNH2AURKAVNN1NAA50 | |
| SCHEMBL23220206 | 0.89 | PTGS1 (0.32) | PTGS1KCNH2AURKAVNN1NAA50 | |
| SCHEMBL20997319 | 0.88 | PTGS1 (0.33) | PTGS1KCNH2AURKAVNN1NAA50 | |
| SCHEMBL23477174 | 0.87 | AURKA (0.37) | PTGS1KCNH2AURKAVNN1NAA50 | |
| SCHEMBL21515142 | 0.87 | AURKA (0.37) | PTGS1KCNH2AURKAVNN1NAA50 | |
| SCHEMBL21515346 | 0.87 | AURKA (0.37) | PTGS1KCNH2AURKAVNN1NAA50 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210170043-A1 | DC-SIGN ANTIBODY CONJUGATES COMPRISING STING AGONISTS | CHINOOK THERAPEUTICS, INC. | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210170043-A1 | DC-SIGN ANTIBODY CONJUGATES COMPRISING STING AGONISTS | STING1, TLR9, TLR3 | PTGS1 3601/4885KCNH2 4437/4885AURKA 952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.